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Abstract
Background: Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–
70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin
(AVP), which is involved in many pathophysiologic processes in CKD. The aim of the present study was to explore
the association of copeptin with VC in CKD stage 5.
Methods: Copeptin was investigated in conjunction with living donor kidney transplantation in 149 clinically stable
CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal
dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53). We analyzed the association of copeptin with presence and
extent of VC ascertained both histologically in biopsies from the inferior epigastric artery (n = 137) and by coronary
artery calcification (CAC) score measured by computed tomography.
Results: Patients with higher copeptin were older, had higher systolic blood pressure, higher prevalence of CVD
and their preceding time on chronic dialysis was longer. In Spearman’s rank correlations (Rho), copeptin
concentrations were significantly associated with CAC score (Rho = 0.27; p = 0.003) and presence of medial VC
(Rho = 0.21; p = 0.016). Multivariate logistic regression analysis showed that 1-SD higher age, male gender, diabetes
and 1-SD higher copeptin were significantly associated with the presence of moderate-extensive VC.
Conclusions: High circulating levels of copeptin in CKD5 patients are independently associated with the degree of
medial calcification ascertained by histology of arterial biopsies. Thus, plasma copeptin may serve as a marker of the
uremic calcification process.
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Background
Chronic kidney disease (CKD) is associated with markedly
increased morbidity and mortality which is mainly a result
of premature cardiovascular disease (CVD) [1–3]. The
causes for the high prevalence of CVD are still not fully elu-
cidated and cannot be explained only by traditional Fra-
mingham risk factors, such as age, hypertension, diabetes
mellitus, dyslipidemia and smoking. In addition, CKD-
specific risk factors, e.g. inflammation, prooxidant-
antioxidant imbalance, protein-energy wasting, disorders in
mineral metabolism and gut dysbiosis, also play a role [2, 4].
Medial vascular calcification (VC), i.e. calcific arterio-
sclerosis, an independent predictor of CVD, is reported
in 30–70% of adult CKD patients, and ≈15% of pediatric
CKD patients [5, 6]. VC develops in the intima together
with atherosclerosis, which is defined as an increase in
the deposition of plaques, and in the media together
with arteriosclerosis, which is associated with vascular
stiffening resulting from the loss of elasticity of muscle
layer of the arterial wall. The presence of VC results in
arterial dysfunction, such as NO-dependent endothelial
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dysfunction [7]. The extent of coronary artery calcifica-
tion (CAC) examined by cardiac computed tomography
(CT) is a useful tool in assessing extent of intima and
medial VC [8, 9]. Medial calcification is predominantly
related to abnormal metabolism in CKD and represents
one of the uremic features entitled CKD – mineral and
bone disorder (CKD-MBD) [10]. Although several bio-
markers, such as calcium, phosphate, alkaline phosphat-
ase, parathyroid hormone, fibroblast growth factor–23
(FGF-23), Klotho, vitamin D3, osteoprotegerin (OPG)
and sclerostin, play important roles in pathological path-
ways of CKD-BMD [11–13], the exact pathogenic mech-
anisms remain unclear and additional factors are likely
to be involved.
Recently, there is increased attention to the role of the
arginine vasopressin (AVP) system, particularly AVP and
copeptin, in the pathophysiological mechanisms of CKD.
AVP, known also as antidiuretic hormone, is produced
in the hypothalamus in the form of a precursor, pre-
proAVP, and released from the posterior pituitary gland
in response to different osmotic and non-osmotic forces.
The principal role of AVP is the control of fluid balance
by promoting water preservation by the kidney, but, in
addition, AVP is involved in the mediation of arteriolar
vasoconstriction and contributes to cardiovascular stabil-
ity [14]. Copeptin, a 39-amino acid glycopeptide with a
leucine-rich core segment and molecular mass of 5 kDa
is derived from the C-terminal portion of the pre-
provasopressin and is co-released with AVP in equimo-
lar amounts. Copeptin is thought to be a reliable, sensi-
tive and easy to measure surrogate marker of AVP [15].
This observation has prompted extensive research re-
garding copeptin – as a surrogate measure of AVP - in
numerous clinical situations. High circulating copeptin
is associated with decline in glomerular filtration rate
and a greater risk of new-onset CKD [16, 17]. Moreover,
high copeptin has been linked with increased risk of
myocardial infarction, heart failure, hypertension, ische-
mic stroke, diabetes mellitus and metabolic syndrome
[14, 18]. In patients with type 1 diabetes, elevated copep-
tin levels were strongly related to diabetic CKD and cor-
onary atherosclerosis [19].
The aim of the present study was to examine the asso-
ciation of copeptin with the presence and extent of CAC
(by CT) and medial VC ascertained in biopsies from the
inferior epigastric artery in CKD5 patients at the time of
living donor kidney transplantation (LD-Rtx).
Methods
Patients and study design
Circulating concentrations of copeptin were measured in
clinically stable CKD 5 patients (n = 149) comprising
non-dialyzed patients (CKD5-ND; n = 53), and dialysis
patients (n = 96) treated by peritoneal dialysis (PD; n =
43) or hemodialysis (HD; n = 53) recruited from an on-
going study on vascular changes before undergoing LD-
Rtx [13]. Their age ranged between 19 and 75 years, 101
(68%) were men, 16 (11%) had diabetes mellitus and 23
(15%) had previously been diagnosed with cerebrovascu-
lar, cardiovascular, and/or peripheral vascular disease
(grouped as CVD).
The characteristics of patients, according to tertiles of
copeptin, are shown in Table 1. Patients were recruited
from March 2009 to February 2017. Exclusion criterion
was unwillingness to participate. Informed consent to
participate in the study – including consent to biopsy of
inferior epigastric artery during transplantation proced-
ure - was obtained from each patient. The Ethics Com-
mittee of the Karolinska Institutet (EPN) approved study
protocols. The studies were conducted in adherence to
the Declaration of Helsinki.
CKD5-ND patients
The causes of renal disease in CKD5-ND patients (n =
53) were chronic glomerulonephritis (n = 27), renovascu-
lar disease or hypertension (n = 2), diabetic nephropathy
(n = 1), other causes or unknown etiology (n = 23).
PD patients
Prevalent PD patients (n = 43) had been treated with bio-
compatible fluids: glucose-based, amino acid-based, or,
for the long dwell, icodextrin-based solutions. Their me-
dian dialysis vintage time was 11.3 months. The causes
of CKD were as follows: chronic glomerulonephritis
(n = 14), renovascular disease or hypertension (n = 1),
diabetic nephropathy (n = 6), other causes or unknown
etiology (n = 22).
HD patients
Prevalent HD patients (n = 53) with median dialysis vin-
tage time of 12.8 months were treated by conventional
maintenance HD or other dialytic techniques. The
causes of CKD were as follows: chronic glomeruloneph-
ritis (n = 15), renovascular disease or hypertension (n =
5), diabetic nephropathy (n = 3), and others or unknown
etiology (n = 30).
Biochemical measurements
Biochemical measurements of plasma high-sensitivity C-
reactive protein (hsCRP), albumin, creatinine, troponin,
cholesterol, triglycerides, HDL-cholesterol, calcium, phos-
phate, alkaline phosphatase (ALP), parathyroid hormone
(PTH), fibroblast growth factor 23 (FGF-23), Klotho, 25
(OH) vitamin D, were performed at the Clinical Chemical
Laboratory of Karolinska University Hospital, Stockholm,
Sweden. Human sclerostin was analyzed with ELISA kit
from R&D systems (Abingdon, UK). LDL was calculated
using the Friedewald formula: [(total cholesterol) - (high-
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Table 1 Characteristics of CKD 5 patients according to tertiles of copeptin
Low (n = 49) Middle (n = 49) High (n = 51) P value
General characteristics
Copeptin (pg/mL) 290 (216–328) 380 (344–438) 520 (455–677) 0.001
Age (years) 45 (24–62) 46 (24–65) 51 (29–67) 0.030
Males, n (%) 32 (65) 33 (67) 36 (71) 0.840
Diabetes mellitus, n (%) 4 (8) 5 (10) 7 (13) 0.663
Cardiovascular disease, n (%) 3 (6) 8 (16) 12 (23) 0.041
Previously on dialysis, n (%) 26 (53) 28 (57) 42 (82) 0.015
Dialysis vintage, years 0.2 (0–3.4) 0.3 (0–3.11) 1.0 (0–3.1) 0.005
Systolic BP, (mmHg) 133 (116–156) 146 (125–170) 144 (115–180) 0.008
Diastolic BP, (mmHg) 80 (67–96) 84 (72–95) 82 (67–100) 0.542
Nutritional status
Body mass index, (kg/m2) 24.4 (21–29.7) 24.5 (20.5–29.9) 25.0 (20.9–29.8) 0.824
Lean body mass index, (kg/m2)a 18.3 (15.3–20.3) 18.6 (14.1–22.1) 18.2 (14.8–21) 0.888
Fat body mass index, (kg/m2)a 5.9 (3.4–10.1) 6.6 (3.6–10.7) 6.1 (3.1–10.1) 0.464
Markers of metabolism and nutrition
Hemoglobin, (g/L)b 110 (97–129) 112 (97–130) 114 (96–131) 0.724
Albumin, (g/L) 35.0 (31.0–40.0) 35.0 (30.0–40.0) 34 (27.4–39.8) 0.388
Glucose, (mmol/L)c 5.4 (4.3–9.2) 5.4 (4.4–7) 5.8 (4.5–8.2) 0.286
HbA1c, (%)d 33.0 (19.0–40.0) 33.5 (25.5–40.5) 33.0 (23.9–40.4) 0.666
Triglyceride, (mmol/L) 1.2 (0.6–2.3) 1.3 (0.6–2.3) 1.4 (0.7–2.6) 0.072
Total cholesterol, (mmol/L) 4.5 (3.2–5.9) 4.4 (3.2–6.2) 4.2 (3.0–6.3) 0.661
HDL cholesterol, (mmol/L) 1.4 (1.0–2.0) 1.4 (0.8–2.2) 1.3 (0.8–2.0) 0.408
LDL cholesterol, (mmol/L) 2.7 (1.6–4.4) 2.6 (1.4–4.5) 2.6 (1.4–4.6) 0.916
Plasma osmolality (mmol/kg) 300 (290–315) 306 (288–319) 302 (290–314) 0.241
Creatinine (μmol/L) 661 (484–1086) 683 (451–1021) 829 (560–1136) 0.006
Biomarkers of inflammation
hsCRP, (mg/L) 0.8 (0.2–9.0) 0.8 (0.2–3.9) 1.0 (0.2–7.0) 0.883
IL-6, (pg/mL)e 1.0 (0.1–6.0) 1.4 (0.1–5.7) 1.4 (0–6.5) 0.820
TNF (pg/mL)f 9.0 (7.2–15.2) 10.8 (8.3–15.2) 10.5 (7.6–21) 0.094
Medications
β-blockers, n (%) 14 (27) 31 (63) 41 (80) < 0.0001
Ca-blocker, n (%) 24 (45) 26 (53) 27 (53) 0.899
ACEi/ARB, n (%) 32 (65) 32 (65) 25 (49) 0.157
Statins, n (%) 15 (31) 16 (33) 21 (41) 0.499
Calcium-phosphate binders, n (%) 24 (49) 28 (57) 26 (51) 0.700
Biomarkers of mineral-bone disease and vascular calcification
Calcium, (mmol/L) 2.3 (2.1–2.6) 2.3 (2.0–2.5) 2.3 (2.0–2.5) 0.814
Phosphate, (mmol/L) 1.7 (1.1–2.1) 1.7 (1.0–2.5) 1.6 (1.0–2.4) 0.964
ALP, (U/L)f 57 (33–109) 60 (38–155) 67 (37–118) 0.505
PTH, (pg/mL) 231 (94–623) 255 (75–594) 269 (54–520) 0.903
FGF-23, (pg/mL)g 3534 (223–27,943) 2820 (706–38,863) 7486 (1088–83,186) 0.257
Klotho (pg/mL)h 317 (178–603) 380 (197–970) 330 (119–513) 0.220
25 (OH) vitamin D 38 (16–79.8) 35 (20–73) 33.5 (12–65.7) 0.309
Sclerostin (pg/mL)i 369 (198–939) 409 (247–682) 515 (271–894) 0.067
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density lipoprotein cholesterol) – (triglycerides/5)]. Tumor
necrosis factor (TNF), interleukin-6 (IL-6) were analyzed
by immunometric assays on an Immulite 1000 Analyzer
(Siemens Healthcare Diagnostics, Los Angeles, CA, USA)
using commercial kits. Plasma osmolality was measured
using VAPRO Vapor Pressure Osmometer 5520 (Wescor,
USA).
Blood samples for copeptin measurement were taken
in patients following overnight fasting, in hemodialyzed
patients samples were taken the day after HD session.
Copeptin concentration was measured with a commer-
cial enzyme immunoassay (Cloud-Clone Corp., Houston,
USA) according to the manufacturer’s protocol. Briefly,
samples were incubated at 37 °C with respective re-
agents. Optical density was read at 450 nm immediately.
The minimum detectable dose of copeptin is typically <
6.1 pg/mL. The intra-assay coefficient variation (CV) was
<10% and the inter-assay CV was <12%.
Nutritional assessments
Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of height in meters. Lean
body mass (LBM) and fat body mass (FBM) were calcu-
lated by anthropometry based on measurements of the
thickness of biceps, triceps, subscapular and supra-iliac
skinfold as described previously [20], using equations by
Siri [21]. LBM index and FBM index were calculated ac-
cording to Kyle et al. [22]. Bone mineral density (BMD)
was determined by dual-energy X-ray absorptiometry
(DXA).
CAC score
Cardiac CT scans were performed using a 64-channel
detector scanner (Lightspeed VCT; General Electric
(GE) Healthcare, Milwaukee, WI). CAC scores were
expressed in Agatston units, the protocol and measure-
ments as described previously in detail [13]. Total CAC
score was calculated as the sum of CAC scores in the
left main artery, the left anterior descending artery, the
left circumflex artery, and the right coronary artery.
Vascular scoring by histology
Inferior epigastric arteries were collected from patients
within 20min from the start of kidney transplantation
procedure. After preparation, the sections were then
stained with hematoxylin and eosin and von Kossa stain-
ing before evaluation by one experienced pathologist.
The degree of medial calcification was quantified semi-
automatically according to method described previously
[13] and graded 0 to 3, where 0 indicated no calcification
and 3 the highest degree of calcification. Patients graded
as 0 and 1 represented no-minimal vascular calcification,
and those graded 2 and 3 represented moderate-
extensive vascular calcification.
Statistical analyses
Continuous data are expressed as median (10th to 90th
percentile) and nominal data as percentage. P value was
set at p < 0.05. For comparisons between three groups
non-parametric Kruskal-Wallis ANOVA-test was used
for continuous variables and Chi-square test was used
for nominal variables. Associations between variables
were determined using non-parametric Spearman rank
correlation analysis. Multivariate linear regression ana-
lyses of copeptin were used and results were shown as
standardized β regression coefficients. We performed
multinomial logistic regression analysis to examine fac-
tors associated for determinants of vascular calcification
0 and 1 score versus 2 and 3. Statistical analyses were
performed using statistical software SAS version 9.4
(SAS Campus Drive, Cary, NC, USA) and Stata 16 (Stata
Corporation, College Station, TX, USA).
Results
Demographics and clinical characteristics of the exam-
ined patients according to copeptin tertiles are shown in
Table 1. Patients with higher copeptin were older, had
Table 1 Characteristics of CKD 5 patients according to tertiles of copeptin (Continued)
Low (n = 49) Middle (n = 49) High (n = 51) P value
Troponin T (μg/L) 17.0 (5.0–53.6) 19.5 (3.6–71.6) 32.0 (1.2–68.0) 0.036
Total BMD (g/cm2)f 1.2 (1.0–1.3) 1.1 (0.9–1.3) 1.1 (0.8–1.3) 0.100
CAC score (AU)j 0 (0–700) 2 (0–1546) 38 (0–1946) 0.055
Medial calcification, n (%)k 0.030
0–1 34 (43) 23 (29) 22 (28)
2–3 13 (22) 20 (35) 25 (43)
Continuous variables are presented as median (10–90 percentile). Categorical variables are presented as number (n)/percentage (%). Abbreviations: Systolic BP
Systolic blood pressure, Diastolic BP Diastolic blood pressure, HDL High-density lipoprotein, LDL Low-density lipoprotein, hsCRP High-sensitivity C-reactive protein,
IL-6 Interleukin-6, TNF Tumor necrosis factor, ACEi Angiotensin-converting enzyme, ARB Angiotensin 2 receptor blocker, ALP Alkaline phosphatase, PTH Parathyroid
hormone, FGF-23 Fibroblast growth factor – 23, Total BMD Total bone mineral density, CAC score (AU) Calcification score (Agatston units)
Measurements were available in following numbers of patients:
a n = 123, b n = 120, c n = 111, d n = 129, e n = 90, f n = 77, g n = 65, h n = 109, i n = 82, j n = 115, k n = 137
Every entry written in boldface in the aforementioned tables is of statistical significance (p < 0,05)
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higher systolic blood pressure and were more frequently
diagnosed with CVD. In addition, higher percentage of
these patients had been undergoing dialysis with longer
vintage. Characteristics of the studied CKD5 patients ac-
cording to dialysis dependence are presented in Add-
itional file 1: Table S1. There was no difference in
copeptin concentration between PD and HD patients
(427 vs. 412 pg/mL, p = 1.0), while plasma copeptin was
significantly lower in CKD5-ND patients compared to
PD and HD patients (351 vs. 427 pg/mL, p = 0.02; and
351 vs. 412 pg/mL, p = 0.001, respectively). Plasma
osmolality and copeptin correlated in CKD5-ND pa-
tients (Rho = 0.28; p = 0.04), whereas in the two groups
of dialyzed patients this association was not observed. In
Spearman’s rank correlations (Rho), copeptin concentra-
tions were significantly associated with age (Rho = 0.21;
p = 0.011), presence of CVD (Rho = 0.20; p = 0.013), sys-
tolic blood pressure (Rho = 0.20; p = 0.01), triglycerides
(Rho = 0.22; p = 0.007), serum creatinine (Rho = 0.26; p =
0.001), TNF (Rho = 0.27; p = 0.016), sclerostin (Rho = 0.22;
p = 0.049), troponin T (Rho = 0.27; p = 0.001), CAC score
(Rho = 0.27; p = 0.003) and histological scoring of medial
calcification (Rho = 0.21; p = 0.016). Copeptin did not have
significant association with gender and diabetes mellitus.
When CAC scores were categorized as CAC = 0, CAC ≥
100 and CAC ≥ 1000, we found no statistically significant
differences in copeptin concentration between the group
of CAC= 0 and CAC ≥ 100 (372.9 [range 259.4–529.8] vs
426.8 [range 242.3–651.8], p = 0.76) but there was statisti-
cally significant difference between the group of CAC = 0
and CAC ≥ 1000 (372.9 [range 259.4–529.8] vs 453.9
[range 333.4–681.1], p = 0.001).
A multivariate linear regression model for determi-
nants for plasma copeptin showed that 1-SD increase of
age, 1-SD increase of serum creatinine and 1-SD in-
crease of triglycerides were associated with higher
plasma copeptin levels (Table 2). Patients with histo-
logical signs of moderate-extensive VC had significantly
higher copeptin levels (Fig. 1).
Univariate analysis showed no significant correlations
between biomarkers of mineral-bone disease and VC;
however, a positive correlation between hsCRP and VC
was found (Rho = 0.18, p = 0.03). Receiver operating charac-
teristic (ROC) curves for prediction of VC showed that the
area under the curve (AUC) was for copeptin – AUC 0.64
(p = 0.02) and for hsCRP - AUC 0.54 (p = 0.02). Multivari-
ate logistic regression analysis showed that 1-SD increase of
age, male gender, presence of diabetes and 1-SD increase of
copeptin were significantly associated with the presence of
moderate-extensive VC (Table 3).
Discussion
We report that in CKD5 patients, high plasma copeptin
levels are associated with age, CVD, dialysis vintage, sys-
tolic blood pressure and serum creatinine. The chief
finding of the study was that elevated copeptin levels
were associated with biopsy-verified media calcification.
Multivariate analysis showed that copeptin was related
to extent of VC independently of age, male gender and
the presence of diabetes.
Vascular calcification, viewed in the past as a passive
process, is now recognized as an active phenomenon [23].
Table 2 Multivariate linear regression for the prediction of
copeptin, pg/ml (n = 149), expressed as standardized β-
coefficients with other variables
Copeptin (adj r2 = 0.14)
Parameters standardized β (p value)
1-SD increase of age, years 0.25 (0.002)
Gender (male, female) −0.08 (0.31)
1-SD increase of serum creatinine (μmol/l) 0.26 (0.003)
1-SD increase of triglyceride (mmol/L) 0.16 (0.03)
Systolic blood pressure (mmHg) 0.14 (0.07)
Every entry written in boldface in the aforementioned tables is of statistical
significance (p < 0,05)
Fig. 1 Plasma copeptin levels in relation to medial calcification
Table 3 Multivariate logistic regression model for determinants
of VC 0 and 1 score versus 2 and 3 (n = 137)
VC (pseudo r2 = 0.29)
Parameters Odds Ratio 95%CI (p value)
1-SD increase of age, years 2.5 (1.5–4.1) (0.001)
Gender (male, female) 4.4 (1.6–11.1) (0.003)
Diabetes (No, Yes) 23.2 (2.5–210.5) (0.005)
CKD5-ND vs HD 0.7 (0.4–1.8) (0.42)
CKD5-ND vs PD 0.5 (0.4–1.8) (0.42)
1-SD increase of hsCRP (mg/L) 0.7 (0.4–1.3) (0.254)
1-SD increase of Copeptin, (pg/ml) 1.6 (1.1–2.6) (0.043)
Every entry written in boldface in the aforementioned tables is of statistical
significance (p < 0,05)
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The mechanisms underlying increased VC in CKD are not
fully explained, but they involve disorders in calcium and
phosphorus metabolism, and disturbed homeostasis in
pro- and anti-calcification factors. Recently, novel tests,
such as T50 functional test, have been developed to help
in the determination of calcification propensity in CKD5
patients [24]. It has also been shown that uremia induces
the differentiation of vascular smooth muscle cells
(VSMCs) – the most important component of the media
of arteries – into osteoblast-like cells due to up-regulation
of transcription factors, such as Runt-related transcription
factor 2 (Runx2) and Msh homebox 2 (Msx2) and in-
creased alkaline phosphatase activity [25]. These changes
contribute to the calcification of VSMC, in a way similar
to bone formation (i.e. ossification).
To the best of our knowledge, this is the first study to
show a link between plasma copeptin level and the de-
gree of VC in CKD. Emerging research suggest that
vasopressin plays important role in the progression of
CKD and hypertension via stimulation of the renin
angiotensin aldosterone system (RAAS) leading to vaso-
constriction and higher systemic and glomerular blood
pressure [18]. Direct effects on VSMCs also result in
vasoconstriction [26]. By modulating both the number
and size of VSMC, AVP may play a direct role in the de-
velopment of chronic vascular disease. It has been re-
ported that AVP activates intracellular Ca2+ and protein
kinase C (PC) via the activation of phospholipase (PL) C
and D leading to augmentation of phosphate transport
during proliferation of VSMC [27, 28]. Among other ac-
tions, AVP also stimulates secretion of endothelin-1
(ET-1) from endothelial cells which enhances endothelial
dysfunction and coagulation disorders as well as in-
creases cellular sodium-dependent phosphate transport
via Pit1 and Pit2 [29, 30]. This suggests, that in the
uremic hyperphosphatemic milieu, there is intensed
entry of phosphate into VSMC. Furthermore, an increase
in cellular phosphate can increase cellular calcification
Fig. 2 Mechanisms of vascular calcification in CKD. In the setting of uraemic milieu, activation of renin-angiotensin and vasopressin systems,
upregulation of sodium-dependent phosphate transporter Pit-1 promotes osteochondrocytic transformation and apoptosis of vascular smooth
muscle cell (VSMC) and, in consequence, accelerated vascular calcification. Dashed lines show possible copeptin links with the process
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by different mechanisms: an increase in calcium x phos-
phate product, change of VSMC to a bone-producing
cell phenotype and cell apoptosis that associates with in-
creased secretion of pro-calcific factors [31]. A sche-
matic presentation of mechanisms leading to VC
including potential links with copeptin is shown in
Fig. 2.
Our study showed positive correlation between
plasma osmolality and copeptin in the group of non-
dialyzed CKD5 patients, whereas such relationship
was not observed in PD and HD groups, and non-
dialyzed patients had also lower plasma copeptin
levels than the other two groups. This accords with
Ettema et al. [32] who examined copeptin levels in
patients with different stages of CKD, including
CKD5. They observed positive correlation between
plasma osmolality and copeptin in patients with
CKD and higher residual renal function (RRF) asso-
ciated with lower plasma copeptin levels in HD pa-
tients which underscore the importance of RRF in
the clearance of copeptin. Finally, they observed that
both vasopressin and copeptin were removed during
HD (with higher dialyzer clearance rate of vasopres-
sin). We recently [33] reported that in patients
undergoing PD, dialysate copeptin was positively cor-
related with plasma copeptin, indicating that also
peritoneal clearance of copeptin may contribute to
explain why there was no association between
plasma copeptin and osmolality among the dialyzed
patients in the current study.
A noteworthy finding of the study is the strong cor-
relation of plasma copeptin with the use of β-
blockers. To the best of our knowledge, such relation-
ship has not been described before. Since the mech-
anism (s) of this correlation remain unclear, further
studies are needed to clarify if this is merely a reflec-
tion of confounding by indication or if β-blockers do
affect copeptin.peter.
The results of the present study should be consid-
ered given some important limitations. First, we
examined CKD5 patients with different types of
treatment; i.e. conservative, HD and PD. Moreover,
since the group in which vascular biopsies were
available was selected for LD-Rtx and thus represent
a selected group of “healthier” CKD5 patients. Thus,
since diabetic nephropathy was underrepresented
compared to the typical CKD5 population the associ-
ation between VC and copeptin may have been
underestimated. Third, as in any observational study,
cause-effect relations cannot be determined. Finally,
although the circulating concentration of copeptin
directly reflects that of AVP and copeptin shows the
same response to osmotic changes as AVP in CKD,
copeptin is reported to increase more than
vasopressin suggesting that the clearance rate of
copeptin is more markedly reduced than for vaso-
pressin when GFR decreases. Thus, while copeptin
reflects vasopressin levels, in CKD stages 4 and 5, a
correction for renal function might be required [14,
32].
Conclusions
High circulating levels of copeptin in CKD5 were
found to associate with total CAC score (by cardiac
CT), and with the degree of medial vascular calcifica-
tion (by histology of arterial biopsies) even after
adjusting for confounders. Further studies are needed
to resolve if copeptin is simply a marker or a player
in the complex uremic vascular calcification process.
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